During childhood, patients with RASopathies (Noonan syndrome and related diseases) can harbor various hematological anomalies ranging from isolated monocytosis, myelemia, thrombocytopenia or splenomegaly to myeloproliferative disorders. These anomalies may spontaneously disappear or persist, sometimes leading to juvenile myelomonocytic leukemia. Guidelines for initial screening and subsequent hematological follow-up have recently been published in France: peripheral blood analysis should be performed in all newly diagnosed patients and followed by biannual peripheral blood analysis in infants until the age of 2 years. In order to describe the characteristics of these abnormalities in terms of their incidence, age of occurrence, evolution and relation to genotype, we are conducting a longitudinal prospective study whose aim is to analyze peripheral blood cell counts and smears at diagnosis and one year later. In patients \<3 years of age recruited at certain centers, biobanking of mononuclear cells will be performed. These data could yield a new insight into hematological anomalies in patients with RASopathies and thereby help physicians to determine the appropriate rhythm for hematological follow-up according to genotype.
Study Type
OBSERVATIONAL
Enrollment
300
CHU Angers
Angers, France
RECRUITINGCHU Caen
Caen, France
RECRUITINGCHU Lille
Lille, France
RECRUITINGCHU Lyon
Lyon, France
RECRUITINGCHU Marseille - Hôpital de la Timone
Marseille, France
RECRUITINGCHU Montpellier
Montpellier, France
RECRUITINGCHU Nantes
Nantes, France
RECRUITINGHôpital Necker APHP
Paris, France
RECRUITINGHôpital Robert Debré APHP
Paris, France
RECRUITINGHôpital Robert Debré APHP
Paris, France
RECRUITING...and 4 more locations
Proportion of patients with hematological abnormalities
Time frame: at inclusion (within 6 months after diagnosis)
Proportion of patients with hematological abnormalities according to genetic abnormality
Time frame: at inclusion (within 6 months after diagnosis)
Proportion of patients with hematological abnormalities according to age
Time frame: at inclusion (within 6 months after diagnosis)
Proportion of patients with hematological abnormalities
Time frame: at 1 year after inclusion
Proportion of patients with hematological abnormalities according to age
Time frame: at 1 year after inclusion
Proportion of patients with hematological abnormalities according to genetic abnormalities
Time frame: at 1 year after inclusion
Evolution of proportion of patients with hematological abnormalities during childhood
Time frame: at 5 years post-inclusion
Event-free survival
Time frame: at one year post-inclusion
Event-free survival
Time frame: at 5 years post-inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.